rift
valley
fever
viru
rvfv
zoonot
mosquitoborn
viru
first
discov
kenya
sinc
spread
becom
endem
much
africa
arabian
peninsula
rift
valley
fever
rvf
caus
recurr
outbreak
febril
ill
associ
high
level
mortal
poor
outcom
pregnancyinclud
foetal
malform
spontan
abort
stillbirthsin
livestock
associ
miscarriag
human
vaccin
avail
human
use
licens
veterinari
use
potenti
drawback
includ
residu
virul
may
contraind
use
pregnanc
address
gap
previous
develop
simian
adenoviru
vector
vaccin
rvf
encod
rvfv
envelop
glycoprotein
rvf
fulli
protect
rvf
nonpregn
livestock
also
develop
human
use
demonstr
administ
pregnant
sheep
goat
rvf
safe
elicit
high
titr
rvfv
neutral
antibodi
provid
protect
viraemia
foetal
loss
although
protect
robust
goat
addit
provid
descript
rvfv
challeng
pregnant
goat
contrast
patholog
observ
pregnant
sheep
togeth
data
support
ongo
develop
rvf
vaccin
use
livestock
human
npj
vaccin
http
doi
rift
valley
fever
viru
rvfv
zoonot
phleboviru
endem
much
africa
arabian
peninsula
viru
transmit
wide
rang
mosquito
speci
caus
numer
outbreak
sinc
discoveri
kenya
rvfv
primarili
affect
livestock
sheep
goat
cattl
camel
caus
clinic
ill
term
rift
valley
fever
rvf
character
extrem
high
rate
neonat
mortal
abort
gestat
livestock
mainli
sheep
goat
human
infect
mainli
occur
contact
rvfvcontamin
tissu
fluid
also
transmit
infecti
mosquito
bite
human
rvf
present
selflimit
febril
ill
progress
sever
lead
lifethreaten
complic
haemorrhag
diathes
enceph
high
case
fatal
rate
among
hospit
individu
debilit
sequela
rvfv
infect
human
placent
tissu
may
underli
recent
observ
associ
rvfv
infect
spontan
abort
stillbirth
pregnant
women
due
lack
specif
therapeut
clinic
manag
rvf
limit
support
therapi
vaccin
avail
human
use
though
licens
veterinari
vaccin
avail
major
drawback
limit
use
instanc
smithburn
vaccin
highli
efficaci
liveattenu
rvfv
vaccin
contraind
gestat
anim
result
abort
foetal
malform
clone
anoth
commerci
avail
livestock
vaccin
base
natur
attenu
rvfv
strain
bear
larg
delet
nss
protein
main
rvfv
virul
factor
whilst
clone
safe
protect
singl
dose
overdos
studi
shown
clone
travers
placent
barrier
caus
foetal
malform
stillbirth
formalininactiv
rvf
vaccin
appli
safe
pregnanc
requir
multipl
booster
optim
efficaci
thu
complic
use
outbreak
situat
human
two
vaccin
evalu
clinic
trial
good
safeti
profil
human
shown
teratogen
livestock
requir
multipl
dose
optim
efficaci
reason
urgent
need
vaccin
provid
protect
singl
vaccin
anim
andor
human
appli
safe
pregnanc
follow
natur
rvfv
infect
longliv
viru
neutral
antibodi
nab
provid
crossprotect
differ
rvfv
strain
gener
induc
nab
target
conserv
viral
envelop
glycoprotein
gn
gc
detect
within
week
postinfect
previous
develop
candid
vaccin
hereaft
term
rvf
base
replicationdefici
simian
adenoviru
vector
encod
rvfv
gn
gc
glycoprotein
singledos
immun
rvf
shown
safe
elicit
high
nab
titr
sheep
goat
cattl
camel
provid
protect
viral
challeng
rvf
vaccin
also
develop
human
use
may
therefor
provid
vaccin
deploy
pathogen
anim
human
support
use
rvf
pregnanc
conduct
studi
examin
safeti
immunogen
efficaci
pregnant
sheep
goat
speci
suffer
greatest
burden
mortal
abort
foetal
malform
rvf
outbreak
rvfv
challeng
studi
previous
conduct
pregnant
goat
studi
also
provid
descript
rvfv
infect
goat
pregnanc
vaccin
safeti
pregnant
ewe
ewe
vaccin
begin
second
trimest
day
day
gestat
respect
fig
anim
vaccin
infecti
unit
rvf
previou
studi
cattl
goat
sheep
shown
dose
highli
effect
ewe
rvf
n
mockvaccin
group
n
good
health
clinic
sign
advers
event
follow
vaccin
rvfvaccin
anim
slight
elev
temperatur
ewe
within
h
vaccin
temperatur
rise
reach
statist
signific
compar
baselin
mannwhitney
u
test
p
speci
normal
day
postvaccin
one
ewe
mockvaccin
group
develop
laryng
chondriti
texel
throat
unrel
studi
euthanis
day
postvaccin
anim
show
clinic
sign
followup
period
challeng
indic
rvf
vaccin
safe
pregnanc
livestock
speci
vaccin
immunogen
efficaci
pregnant
ewe
ensur
compar
previou
rvfv
vaccin
challeng
trial
pregnant
ewe
use
viral
challeng
dose
tcid
challeng
viru
dose
back
titrat
tcid
within
day
rvfv
challeng
mockvaccin
ewe
elev
rectal
temperatur
coincid
loss
appetit
high
level
viraemia
fig
g
one
ewe
die
acut
day
postchalleng
typic
necrot
liver
two
dead
foetus
necropsi
supplementari
tabl
anoth
ewe
abort
one
foetu
day
postchalleng
togeth
autolys
placenta
supplementari
tabl
point
remain
ewe
group
euthanis
prevent
unnecessari
anim
discomfort
total
mockvaccin
group
carri
foetus
found
dead
necropsi
supplementari
tabl
viral
rna
infecti
viru
detect
matern
liver
spleen
foetal
liver
brain
spleen
placentom
fig
hematoxylin
eosin
h
e
stain
placentom
mockvaccin
ewe
reveal
extens
haemorrhag
area
necrosi
matern
epithelium
foci
miner
fig
e
right
column
rvfvspecif
immunohistochemistri
ihc
confirm
presenc
rvfv
antigen
matern
foetal
epitheli
cell
fig
f
right
column
alizarin
red
stain
confirm
presenc
calcium
deposit
fig
right
column
contrast
rvfvaccin
ewe
mount
high
titr
nab
rvfv
fig
show
clinic
sign
viraemia
rvfv
challeng
fig
g
none
ewe
develop
antibodi
rvfv
n
protein
absent
rvf
vaccin
present
challeng
viru
challeng
suggest
vaccin
confer
steril
immun
speci
fig
follow
euthanasia
necropsi
end
studi
rvfvaccin
ewe
found
carri
healthi
foetus
expect
size
supplementari
tabl
detect
viral
rna
matern
organ
blood
foetal
organ
placentom
ihc
stain
placentom
show
specif
stain
rvfv
antigen
fig
f
left
column
foci
miner
observ
placentom
ewe
impact
health
foetus
viral
rna
could
detect
placentom
fig
vaccin
immunogen
efficaci
pregnant
follow
rvfv
challeng
mockvaccin
group
n
show
clinic
sign
infect
includ
listless
reduc
appetit
transient
increas
rectal
temperatur
start
day
postchalleng
associ
high
level
viraemia
fig
h
two
abort
autolys
foetus
day
postchalleng
cull
reach
human
endpoint
supplementari
tabl
remain
n
euthanis
day
postchalleng
prevent
unnecessari
discomfort
necropsi
three
six
found
carri
foetus
like
pseudopregn
confirm
retrospect
low
level
pregnancyassoci
glycoprotein
measur
elisa
foetus
three
remain
pregnant
dead
autolys
necropsi
supplementari
tabl
high
viral
rna
level
detect
matern
foetal
tissu
fig
viru
could
isol
almost
exclus
placentom
due
autolys
statu
foetus
necropsi
fig
ihc
stain
placentom
reveal
strong
stain
rvfv
antigen
larg
area
necrot
matern
epithelium
miner
observ
h
e
alizarin
red
stain
fig
right
column
howev
strong
contrast
mockvaccin
ewe
extens
haemorrhag
observ
placenta
mockvaccin
rvfvaccin
develop
rvfv
nab
fig
remain
complet
healthi
follow
challeng
clinic
sign
viraemia
fig
h
three
rvfvaccin
develop
antibodi
rvfv
n
protein
challeng
doe
number
suggest
challeng
viru
underw
replic
host
follow
infect
two
other
doe
number
zone
neg
posit
elisa
valu
consid
doubt
fig
challeng
viru
replic
occur
despit
fact
rvfv
nab
titr
averag
five
time
higher
ewe
replic
occur
geometr
end
studi
rvfvaccin
found
carri
total
appar
healthi
foetus
expect
size
two
autolys
foetus
may
succumb
postchalleng
base
crown
rump
valu
lower
consid
posit
consid
doubt
consid
neg
dot
line
repres
inhibit
sampl
test
neg
viraemia
depict
detect
limit
rtqpcr
assay
rna
copiesml
data
depict
mean
standard
error
p
valu
mannwhitney
u
test
compar
prechalleng
vnt
titr
measur
day
c
viraemia
level
day
postchalleng
g
h
mockand
rvfvaccin
anim
shown
p
length
fig
supplementari
tabl
autolys
foetus
part
multifoet
pregnanc
two
doeson
doe
carri
five
foetus
anoth
carri
threebut
remain
foetus
carri
appear
healthi
necropsi
organ
sampl
brain
liver
spleen
appar
healthi
foetus
addit
assess
abnorm
extens
histolog
analys
reveal
sign
patholog
sampl
none
matern
tissu
rvfvaccin
posit
viral
rna
fig
howev
low
level
viral
rna
could
detect
plasma
placentom
foetus
harvest
four
eight
one
except
viru
isol
placentom
fig
lack
detect
rvfv
antigen
immunohistolog
placentom
live
foetus
explain
detect
limit
assay
studi
group
foci
miner
deposit
observ
placentom
fig
previous
demonstr
rvf
safe
highli
immunogen
provid
complet
protect
rvf
multipl
target
livestock
speci
earlier
studi
underpin
develop
vaccin
larger
ongo
livestock
field
trial
support
registr
product
veterinari
use
rvf
also
due
enter
human
phase
clinic
trial
soon
inform
potenti
use
vaccin
construct
control
rvf
livestock
human
ongo
futur
studi
aim
address
unmet
need
human
rvf
vaccin
safer
veterinari
rvf
vaccin
altern
howev
safeti
rvf
vaccin
pregnanc
well
immunogen
protect
efficaci
viral
challeng
physiolog
state
remain
unknown
studi
address
knowledg
gap
evalu
safeti
immunogen
efficaci
rvf
sheep
goat
two
main
livestock
speci
bear
brunt
abort
poor
gestat
outcom
rvf
outbreak
pregnant
ewe
immun
singl
dose
rvf
show
advers
reaction
remain
healthi
fever
pregnanc
loss
postvaccin
period
viral
challeng
despit
fact
vaccin
perform
first
trimest
foetu
suscept
abort
malform
follow
vaccin
current
licens
veterinari
vaccin
fig
frequenc
viral
rna
detect
viru
isol
foetal
matern
tissu
speci
dam
foetu
result
rtqpcr
detect
detect
limit
rna
copiesml
plasma
viru
isol
detect
limit
rna
copiesml
organ
suspens
shown
post
necropsi
time
necropsi
vari
group
rvf
dpc
mockvaccin
dpc
placentom
combin
matern
foetal
tissu
sampl
posit
rtqpcr
colour
code
whilst
green
use
rtqpcr
neg
grey
shade
repres
sampl
avail
due
autolysi
sampl
infecti
viru
could
isol
mark
asterisk
posit
rtqpcr
sampl
subject
viral
isol
na
applic
number
pseudopregn
henc
foetus
analysi
stedman
et
al
develop
high
titr
rvfv
nab
could
detect
earli
day
postvaccin
rvf
contain
rvfv
nucleoprotein
n
present
whole
rvfv
wide
use
diagnost
elisa
detect
antin
antibodi
use
distinguish
infect
vaccin
anim
diva
inde
mockvaccin
anim
develop
antin
antibodi
respons
follow
challeng
rvfv
whilst
rvfvaccin
ewe
fulli
protect
foetal
loss
viraemia
develop
antin
antibodi
rvfvaccin
develop
antin
antibodi
despit
absenc
detect
viraemia
suggest
viru
replic
complet
block
rapid
induct
protect
nab
togeth
diva
compat
make
rvf
wellsuit
respons
outbreak
rvf
fulli
protect
clinic
sign
viraemia
pregnant
ewe
howev
whilst
foetus
rvfvaccin
ewe
free
viral
rna
tissu
plasma
necropsi
four
eight
rvfvaccin
evid
low
level
viral
rna
plasma
placentom
live
viru
isol
one
placentom
despit
rvfv
nab
titr
averag
five
time
higher
sheep
day
viral
challeng
remark
rvf
vaccineinduc
immun
respons
clearli
suffici
prevent
matern
viraemia
clinic
sign
studi
nonpregn
goat
previou
studi
kenya
one
possibl
immun
mechan
respons
protect
utero
infect
goat
differ
sheep
futur
studi
help
address
conclus
analys
includ
correl
gestat
outcom
challeng
viru
dose
rout
viral
exposur
qualiti
humor
cellular
immun
respons
goat
breed
put
host
factor
nonpregn
goat
inde
show
variabl
natur
cours
rvfv
infect
depend
upon
breed
goat
age
challeng
strain
rout
inocul
viral
rna
follow
rvfv
challeng
detect
day
postchalleng
nonpregn
goat
spleen
calv
sheep
day
postchalleng
suggest
anim
recov
rvfv
infect
may
harbour
low
viru
level
tissu
extend
period
given
rvfv
tropism
placent
tissu
find
viral
rna
placentom
day
postchalleng
studi
therefor
surpris
observ
foci
miner
calcium
deposit
placentom
anim
necropsi
despit
placenta
look
healthi
macroscop
miner
due
rvf
vaccin
also
found
mockvaccin
ewe
goat
bore
clinic
signific
foci
rel
small
compar
total
area
placentom
miner
describ
previous
virul
rvfv
challeng
studi
done
pregnant
anim
though
viral
challeng
studi
done
later
gestat
second
trimest
vaccin
anim
follow
full
term
follow
challeng
like
explan
miner
indic
inflamm
follow
viral
infect
note
infecti
diseas
anim
human
high
intraven
challeng
dose
use
studi
would
ensur
rapid
dissemin
viru
placenta
other
tissu
rvfv
tropism
thu
initi
strong
host
inflammatori
respons
plausibl
altern
inocul
rout
eg
subcutan
intranas
mosquito
bite
may
result
slower
rate
placent
infect
minim
histolog
evid
inflamm
altern
miner
may
incident
occur
latter
summari
shown
rvf
vaccin
safe
use
pregnant
sheep
goat
elicit
high
titr
rvfv
nab
provid
protect
foetal
loss
also
provid
descript
patholog
rvfv
infect
pregnant
goat
compar
pregnant
sheep
stage
gestat
use
viru
challeng
strain
dose
inocul
rout
foetus
rvfvaccin
goat
fulli
protect
despit
significantli
higher
rvfv
nab
titr
rvfvaccin
sheep
whose
foetus
protect
suggest
differ
key
mechan
protect
foetal
infect
two
speci
studi
compar
immun
respons
divers
livestock
speci
affect
rvfv
requir
fulli
determin
basi
efficaci
differ
may
inform
develop
vaccin
protect
pregnant
women
rvf
anim
experi
conduct
netherland
accord
dutch
law
anim
experi
wet
op
de
dierproeven
id
number
european
regul
eu
direct
protect
anim
use
scientif
purpos
procedur
approv
anim
ethic
committe
wageningen
bioveterinari
research
wbvr
dutch
central
author
scientif
procedur
anim
permit
number
addit
studi
review
approv
pirbright
institut
anim
ethic
committe
rvf
vaccin
encod
rvfv
gn
gc
code
sequenc
genbank
access
number
construct
gateway
recombin
vector
entri
plasmid
contain
rvfv
gn
gc
code
sequenc
virul
rvfv
strain
use
anim
challeng
anim
studi
design
studi
design
determin
safeti
immunogen
efficaci
rvf
vaccin
pregnant
ewe
goat
see
fig
schemat
studi
plan
oestru
cycl
texel
crossbre
ewe
saanen
age
year
synchron
use
progesteron
spong
prior
mate
ram
buck
breed
thirtynin
fortysix
day
later
ewe
scan
pregnanc
ultrasound
gestat
anim
speci
select
gener
health
anim
base
absenc
clinic
sign
ill
confirm
local
veterinarian
prior
transport
anim
anim
facil
week
acclim
anim
day
gestat
vaccin
intramuscularli
right
brachiocephalicu
muscl
either
infecti
unit
studi
vaccin
rvf
n
ml
vaccin
diluent
steril
phosphat
buffer
salin
pb
ml
vaccin
diluent
mockvaccin
group
n
use
vaccin
diluent
appropri
control
sinc
never
observ
protect
confer
irrelev
adenoviru
vector
use
vaccin
studi
assess
protect
efficaci
anim
challeng
intraven
tcid
rvfv
ref
day
postvaccin
day
gestat
anim
monitor
daili
gener
health
rectal
temperatur
sign
abort
throughout
cours
studi
anim
euthanis
end
studi
week
postchalleng
reach
human
endpoint
serum
sampl
collect
weekli
throughout
studi
measur
antibodi
respons
viraemia
monitor
done
plasma
collect
day
challeng
day
daili
postchalleng
day
thereaft
specifi
time
point
sampl
necropsi
taken
liver
spleen
placenta
dam
liver
spleen
brain
foetus
addit
sampl
collect
organ
show
abnorm
organ
sampl
place
ice
necropsi
subsequ
store
tissu
sampl
histolog
ihc
collect
place
formalin
embed
paraffin
prepar
h
e
stain
alizarin
red
merck
darmstadt
germani
stain
calcium
ihc
stain
rvfv
antigen
use
rvfv
gnspecif
monoclon
antibodi
laboratori
assay
organ
sampl
tissu
plasma
sampl
prepar
test
presenc
rvfv
rna
rtqpcr
viral
rna
isol
nuclisen
easymag
system
accord
manufactur
instruct
biomerieux
franc
either
ml
plasma
ml
organ
suspens
organ
sampl
homogen
prepar
use
ultraturrax
system
combin
tube
ika
staufen
germani
briefli
ml
cultur
medium
ad
g
tissu
sampl
homogen
cell
debri
remov
slowspe
centrifug
five
microlitresa
rna
subsequ
use
rtqpcr
use
lightcycl
rna
amplif
kit
hybprob
roch
almer
netherland
combin
lightcycl
realtim
pcr
system
roch
onetub
rtqpcr
perform
use
forward
primer
rv
aaaggaacaatggactctggtca
revers
primer
rva
cacttcttactaccatgtcctccaat
famlabel
probe
rvp
aaagctttgatatctctcagtgccccaa
viru
isol
perform
rtqpcr
posit
sampl
threshold
rna
copiesml
previous
shown
cutoff
point
live
viru
detect
presenc
rvfv
nucleoproteinspecif
antibodi
sera
determin
use
id
rift
valley
fever
competit
elisa
idvet
montpelli
franc
serum
rvfv
nab
measur
use
viru
neutral
test
vnt
briefli
plate
format
serial
dilut
heatinactiv
sera
h
incub
h
room
temperatur
subsequ
cell
ad
well
plate
incub
day
co
score
use
evosfl
microscop
life
technolog
vnt
titr
calcul
use
algorithm
statist
analys
statist
comparison
studi
group
done
use
nonparametr
test
twosid
p
cutoff
statist
signific
analys
done
graphpad
prism
inform
research
design
avail
natur
research
report
summari
link
articl
data
gener
analyz
studi
includ
publish
articl
receiv
juli
accept
septemb
